UPDATE: Canaccord Genuity Starts NewLink Genetics (NLNK) at Buy; See Near-Term Catalyst
Tweet Send to a FriendGet Alerts NLNK Hot Sheet
Price: $16.10 +0.37%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade NLNK Now!
(Updated - June 1, 2012 8:24 AM EDT)
Canaccord Genuity assumes coverage on NewLink Genetics (NASDAQ: NLNK) with a Buy. PT $23.00.
Analyst, Salveen Richter, said, "The key value driver is HyperAcute Pancreas (HAP) – a novel immunotherapy in P3 clinical trial for surgically-resected pancreatic cancer. A positive P2 (we recognize it was a single-arm study) in addition to the novel cancer vaccine platform are encouraging as we look toward P3 data (first interim analysis in late-2012/early-2013E). We model for peak worldwide HAP sales of $850M in 2020, of which $635M is recognized by NLNK. We view the remainder of the pipeline as a free-call option. While NLNK shares are up ~81% YTD, we believe long-term P2 overall survival data at ASCO (June 4) could serve as a near-term catalyst."
For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.
Shares of NewLink Genetics closed at $12.76 yesterday, with a 52 week range of $6.25-$13.67.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Canaccord Genuity assumes coverage on NewLink Genetics (NASDAQ: NLNK) with a Buy. PT $23.00.
Analyst, Salveen Richter, said, "The key value driver is HyperAcute Pancreas (HAP) – a novel immunotherapy in P3 clinical trial for surgically-resected pancreatic cancer. A positive P2 (we recognize it was a single-arm study) in addition to the novel cancer vaccine platform are encouraging as we look toward P3 data (first interim analysis in late-2012/early-2013E). We model for peak worldwide HAP sales of $850M in 2020, of which $635M is recognized by NLNK. We view the remainder of the pipeline as a free-call option. While NLNK shares are up ~81% YTD, we believe long-term P2 overall survival data at ASCO (June 4) could serve as a near-term catalyst."
For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.
Shares of NewLink Genetics closed at $12.76 yesterday, with a 52 week range of $6.25-$13.67.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold
- Stifel Nicolaus Starts LKQ Corp. (LKQ) at Buy
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
